Rockwell Medical files new drug submission with Health Canada for marketing approval of Triferic AVNU

Rockwell Medical

26 May 2020 - Rockwell Medical today announced the filing of a new drug submission with Health Canada for Triferic AVNU (ferric pyrophosphate citrate). 

The Company seeks an indication to promote Triferic AVNU in Canada for the replacement of iron to maintain haemoglobin in adult patients with haemodialysis dependent chronic kidney disease. 

The filing is the first international regulatory submission for the intravenous therapy.

Read Rockwell Medical press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , Canada , Dossier